ProfileGDS4814 / ILMN_1805395
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 85% 82% 80% 85% 84% 82% 82% 83% 85% 82% 84% 86% 81% 82% 83% 82% 82% 83% 84% 82% 85% 83% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)221.20185
GSM780708Untreated after 4 days (C2_1)173.61682
GSM780709Untreated after 4 days (C3_1)146.03580
GSM780719Untreated after 4 days (C1_2)231.77185
GSM780720Untreated after 4 days (C2_2)214.10484
GSM780721Untreated after 4 days (C3_2)166.18582
GSM780710Trastuzumab treated after 4 days (T1_1)166.52282
GSM780711Trastuzumab treated after 4 days (T2_1)198.79883
GSM780712Trastuzumab treated after 4 days (T3_1)237.82585
GSM780722Trastuzumab treated after 4 days (T1_2)171.16982
GSM780723Trastuzumab treated after 4 days (T2_2)216.04484
GSM780724Trastuzumab treated after 4 days (T3_2)265.30686
GSM780713Pertuzumab treated after 4 days (P1_1)157.31681
GSM780714Pertuzumab treated after 4 days (P2_1)168.29882
GSM780715Pertuzumab treated after 4 days (P3_1)181.11383
GSM780725Pertuzumab treated after 4 days (P1_2)179.23582
GSM780726Pertuzumab treated after 4 days (P2_2)179.982
GSM780727Pertuzumab treated after 4 days (P3_2)185.19883
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)214.28484
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)174.97182
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)223.01185
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)197.12883
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)224.95785